Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

by Wu, Yi-Long , Kowalski, Dariusz , John, Thomas , de Marinis, Filippo , Rukazenkov, Yuri , Tsuboi, Masahiro , Majem, Margarita , Shepherd, Frances A. , Wang, Jie , Kato, Terufumi , Le, Nhieu Thi , Dechaphunkul, Arunee , Poole, Lynne , Herbst, Roy S. , Lee, Ki Hyeong , Lu, Shun , Su, Wu-Chou , Grohé, Christian , Bolanos, Ana , Goldman, Jonathan W.

in Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - surgery / Chemotherapy / Coronaviruses / COVID-19 / COVID-19 - etiology / Critical Care / Critical Care General / Epidermal growth factor receptors / ErbB Receptors - genetics / Hematology / Humans / Lung Cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Lung Neoplasms - surgery / Mutation / Neoplasm Recurrence, Local - drug therapy / Non-small cell lung carcinoma / Oncology / Patients / Placebos / Pulmonary / Small cell lung carcinoma / Survival Analysis / Targeted cancer therapy / Treatments in Oncology

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

2023

Confirm

Do you wish to request the book?

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Wu, Yi-Long,

Kowalski, Dariusz,

John, Thomas,

de Marinis, Filippo,

Rukazenkov, Yuri,

Tsuboi, Masahiro,

Majem, Margarita,

Shepherd, Frances A.,

Wang, Jie,

Kato, Terufumi,

Le, Nhieu Thi,

Dechaphunkul, Arunee,

Poole, Lynne,

Herbst, Roy S.,

Lee, Ki Hyeong,

Lu, Shun,

Su, Wu-Chou,

Grohé, Christian,

Bolanos, Ana,

Goldman, Jonathan W.

2023

Overview

Patients with resected, EGFR -mutated, stage IB to IIIA NSCLC were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. The 5-year overall survival was 88% with osimertinib and 78% with placebo.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Cancer therapies

/ Carcinoma, Non-Small-Cell Lung - drug therapy

/ Carcinoma, Non-Small-Cell Lung - genetics

/ Carcinoma, Non-Small-Cell Lung - mortality

/ Carcinoma, Non-Small-Cell Lung - surgery

/ Chemotherapy